TFS Capital’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

TFS Capital’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,103	Closed	-$158K	–	792
2017 Q1	$158K	Buy	+1,103	New	+$158K	0.05%	542
2016 Q2	–	Sell	-122	Closed	-$14K	–	1211
2016 Q1	$14K	Sell	122 -116	-49%	-$17.6K	﹤0.01%	978
2015 Q4	$45K	Sell	238 -859	-78%	-$161K	﹤0.01%	709
2015 Q3	$187K	Buy	+1,097	New	+$396K	0.02%	749
2014 Q3	–	Sell	-289	Closed	-$396K	–	1243
2014 Q2	$396K	Sell	289 -350	-55%	-$406K	0.03%	731
2014 Q1	$887K	Buy	+639	New	+$743K	0.06%	509

Other funds holding VIRX

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

TFS Capital's VIRX Position: Q2 2017 in Review

TFS Capital sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2017, closing a stake of 1,103 shares — an estimated $158K sold.

TFS Capital first reported a position in VIRX in Q1 2014 and held it in 6 quarters. The position peaked at $887K in Q1 2014. 37 funds tracked by Wall St. Rank hold VIRX as of Q2 2017.

TFS Capital reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
TFS Capital sold 1,103 Viracta Therapeutics, Inc. Common Stock shares in Q2 2017, an estimated $158K.
TFS Capital first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2014 and held it in 6 quarters.
TFS Capital's Viracta Therapeutics, Inc. Common Stock position peaked at $887K in Q1 2014.
37 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2017.

Based on TFS Capital's 13F filing for Q2 2017, filed 11 Aug 2017.